

Press Information

BIOCERAM AZUL® by Kyocera: Innovation and strategy in the spotlight at DKOU 2024

Rethinking medical technology – Kyocera embraces future-ready solutions

Kyoto/Esslingen, 7th November 2024. KYOCERA Fineceramics Medical GmbH (KFMG) showcased its innovative ceramic solution, BIOCERAM AZUL®, for hip endoprostheses at DKOU 2024, held in Berlin from October 22 to 25. A highlight of the event was the lunch symposium on October 23, where industry representatives, surgeons, and materials scientists gained deep insights into the material and clinical properties of BIOCERAM AZUL®.

BIOCERAM AZUL® – an innovative material for hip prostheses

Already a success in Japan, Kyocera impressed attendees at DKOU with BIOCERAM AZUL® in its European debut. Known for its high fracture toughness and excellent biocompatibility, the material offers a pioneering solution in hip endoprosthetics. During the lunch symposium, Dr. Fabian Preuß, Prof. Michael Morlock, Dr. Taro Umezue, and Prof. Stelter discussed the material's benefits and clinical performance. Moderated by Prof. Dieter Wirtz, the session provided a comprehensive outlook on the future of medical ceramic technology.

Kyocera's long-term strategy in medical technology

Dr. Fabian Preuß, Managing Director of KYOCERA Fineceramics Medical GmbH, presented the company's long-term strategy, emphasizing future growth: "Our goal is to enter the market as a strategic supplier of ceramic femoral heads for hip prostheses, providing reliable solutions to our customers. In the second phase, we aim to position ourselves as a strategic partner for all types of medical ceramic solutions within the human body, ultimately becoming the leading company in medical ceramics."

Kyocera's commitment to the European market

Kyocera's presence at DKOU 2024 represents a significant milestone for the company and highlights its commitment to the European medical technology market. In addition to BIOCERAM AZUL®, KFMG is planning to expand its product portfolio, supported by a new production facility in Waiblingen, which is set to open in 2025. This facility will manufacture high-quality medical ceramic products for the global market, addressing the growing demand for biocompatible and durable solutions.



BIO CERAM AZUL® ceramic ball by Kyocera

About DKOU 2024

The [DKOU](#) is the largest European congress for orthopedics and trauma surgery, providing a central platform for sharing the latest technological and clinical developments.



Dr. Fabian Preuß, Dr. Taro Umezu, Prof. Stelter, Prof. Michael Morlock, and Prof. Dieter Wirtz presented the successes and future opportunities of BIO CERAM AZUL® in medical technology.



For more information on Kyocera: uk.kyocera.com

About Kyocera

Kyocera has been successful in Europe for over 50 years. From its European headquarters in Esslingen am Neckar, KYOCERA Europe GmbH operates 27 sites including manufacturing facilities, with products ranging from fine ceramics, electronics, automotive, semiconductor and optical components to industrial tools, LCDs, touch solutions, industrial printing components, solar systems and consumer goods such as kitchen and office products.

Kyocera's high-performance ceramic products are produced and distributed by [KYOCERA Fineceramics Europe GmbH](#), a subsidiary of KYOCERA Europe GmbH. [KYOCERA Fineceramics Medical GmbH](#) is part of KYOCERA Fineceramics Europe GmbH and is set to begin delivering medical products in the first quarter of 2026. The Kyocera Group is one of the world's leading providers of high-performance ceramic components for the technology industry, offering over 200 different ceramic materials, as well as state-of-the-art technologies and services tailored to the specific needs of each market.

KYOCERA Europe GmbH is a company of the KYOCERA Corporation headquartered in Kyoto/Japan, a world leader in semiconductor, industrial and automotive components as well as electronic components, printing and multifunction systems, and communications technology. The technology group is one of the world's most experienced manufacturers of smart energy systems, with more than 45 years of industry expertise. The Kyocera Group comprises 292 subsidiaries (31 March 2024). In England, Kyocera has a subsidiary in Frimley, KYOCERA Fineceramics Ltd. With around 79,200 employees, Kyocera generated net annual sales of around EUR 12.29 billion in the 2023/2024 fiscal year.

Kyocera is ranked 672 on Forbes magazine's 'Global 2000' list for 2023, and ranked as 'The 100 Most Sustainably Managed Companies in the World' according to the Wall Street Journal. For the second year in a row, Kyocera qualified for the Dow Jones Sustainability Index (Asia-Pacific). As well, Kyocera receives a Gold rating on EcoVadis Sustainability Survey for the second consecutive year and was acknowledged as a 'Top 100 Global Innovator 2023', being one of the world's leading innovators, for the eighth time by Clarivate.

The company also takes an active interest in cultural affairs. The Kyoto Prize, a prominent international award, is presented each year by the Inamori Foundation — established by Kyocera founder Dr Kazuo Inamori — to individuals worldwide who have contributed significantly to the scientific, cultural, and spiritual betterment of humankind (equivalent to approximately €596,500 per prize category).

Contact

KYOCERA Europe GmbH
Andrea Berlin
Fritz-Müller-Straße 27
73730 Esslingen / Germany
Tel: +49 711/93 93 48 96
Mobil: +49 151 16 33 07 93
E-Mail: PR@kyocera.de
uk.kyocera.com